Skip to content
Back to recalls
Drug FDA Class II Ongoing Sub/super-potent

Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy

Boothwyn Pharmacy LLC Published Sep 10, 2025

Risk level

Class II

May cause a temporary or reversible health problem; slight chance of serious harm.

Severity score 60/100

What should you do?

  • Check whether you have this product, using the lot codes, UPCs, and dates listed below.
  • Do not eat, serve, or sell the affected product.
  • Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
  • Contact Boothwyn Pharmacy LLC or your place of purchase with questions, and see the source record below for full details.
Reason for recall

Subpotent Drug

Hazards

Subpotency · primary

Affected products (1)

Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy

642 vials

Code info: 03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025

Affected areas

Nationwide

Timeline

  1. Initiated
    Jul 9, 2025
  2. Published
    Sep 10, 2025
Recall number
D-0606-2025
Agency
U.S. Food and Drug Administration
Country
US
Source data (openFDA JSON) About FDA enforcement reports

FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.